What can rehabilitation interventions achieve in patients with primary fibromyalgia?

Current Opinion in Rheumatology

Volumn 15, Issue 2, 2003, Pages 145-150

  Sprott, Haiko ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BETA ENDORPHIN; FLUOXETINE; GLUCOCORTICOID; KETAMINE; LIDOCAINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT;

BALNEOTHERAPY; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; DISEASE CLASSIFICATION; DRUG EFFICACY; FIBROMYALGIA; HUMAN; KINESIOTHERAPY; LOW LEVEL LASER THERAPY; MEDICAL ASSESSMENT; PALLIATIVE THERAPY; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; STRESS; TREATMENT OUTCOME;

ANALGESICS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; EXERCISE; FEMALE; FIBROMYALGIA; HUMANS; MALE; PAIN MEASUREMENT; PHYSICAL THERAPY MODALITIES; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0037371573     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200303000-00011     Document Type: Review

References (72)

1. Baumgartner E, Finckh A, Cedraschi C, et al.: A six year prospective study of a cohort of patients with fibremyalgia. Ann Rheum Dis 2002, 61:644-645.
2. Ahles TA, Yunus MB, Riley SD, et al.: Psychological factors associated with primary fibromyalgia syndrome. Arthritis Rheum 1984, 27:1101-1106.
3. Uveges JM, Parker JC, Smarr KL, et al.: Psychological symptoms in primary fibromyalgia syndrome: relationship to pain, life stress, and sleep disturbance. Arthritis Rheum 1990, 33:1279-1283.
4. Sprott H, Franke S, Kluge H, et al.: Pain treatment of fibromyalgia with acupuncture. Rheumatol Int 1998, 18:35-36.
5. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multi-center Criteria Committee. Arthritis Rheum 1990, 33:160-172.
6. Quintner JL, Cohen ML: Fibromyalgia falls foul of a fallacy. Lancet 1999, 353:1092-1094.
7. Hadler NM: Fibromyalgia: la maladie est morte. Vive le malade! J Rheumatol 1997, 24:1250-1252.
8. King SJ, Wessel J, Bhambhani Y, et al.: Predictors of success of intervention programs for persons with fibromyalgia. J Rheumatol 2002, 29:1034-1040. • Select sociodemographic and psychosocial variables and type of intervention were not strong predictors of improvement in a variety of measures after a treatment program because of the heterogeneity of FM.
9. Hurtig IM, Raak RI, Kendall SA, et al.: Quantitative sensory testing in fibromyalgia patients and in healthy subjects: identification of subgroups. Clin J Pain 2001, 17:316-322.
10. Sprott H, Salemi S, Michel BA, et al.: Subgroups in fibromyalgia. Ann Rheum Dis 2002, 61 (suppl 1):453-454.
11. Sorensen J, Bengtsson A, Ahlner J, et al.: Fibromyalgia: are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997, 24:1615-1621.
12. Ahles TA, Yunus MB, Gaulier B, et al.: The use of contemporary MMPI norms in the study of chronic pain patients. Pain 1986, 24:159-163.
13. Ahles TA, Yunus MB, Masi AT: Is chronic pain a variant of depressive disease? The case of primary fibromyalgia syndrome. Pain 1987, 29:105-111.
14. Cianfrini L, Bradley L, Sotolongo A, et al.: Verbal and physiologic responses to pain differ in patients with fibromyalgia (FM) and major depression (MD) [abstract]. IASP Press 2002, 526-P160.
15. Walsh NE, Dumitru D, Ramamurthy S, et al.: Treatment of the patient with chronic pain. In Rehabilitation Medicine. Edited by DeLisa JA, Gans BM. Philadelphia, Lippincott Company; 1993.
16. Jones KD, Clark SR, Bennett RM: Prescribing exercise for people with fibromyalgia. AACN Clin Issues 2002, 13:277-293. • Exercise that combats deconditioning without triggering pain is a key component in treating FM. Therefore, disease-specific exercises for people with FM must be prescribed.
17. Campbell SM, Clark S, Tindall EA, et al.: Clinical characteristics of fibrositis. I: A 'blinded' controlled study of symptoms and tender points. Arthritis Rheum 1983, 26:817-824.
18. Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
19. Bennett RM: Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 1996, 39:1627-1634.
20. Guler M, Kirnap M, Bekaroglu M, et al.: Clinical characteristics of patients with fibromyalgia. Isr J Med C 1992, 28:20-23.
21. Buskila D, Neumann L, Herchman E, et al.: Fibromyalgia syndrome in children: an outcome study. J Rheumatol 1995, 22:525-528.
22. Borg-Stein J: Management of peripheral pain generators in fibromyalgia. Rheum Dis Clin North Am 2002, 28:305-317. •• Part of the comprehensive pain management of patients with FM should include a thoughtful evaluation and search for peripheral pain generators that either are associated with FM or are coincidentally present. The identification and treatment of these pain generators lessens the total pain burden, facilitates rehabilitation, and decreases the stimuli for ongoing central sensitization.
23. Karjalainen K, Malmivaara A, van Tulder M, et al.: Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. The Cochrane Library (Oxford) 2002 (CD001984).
24. Mason LW, Goolkasian P, McCain GA: Evaluation of a multimodal treatment program for fibromyalgia. J Behav Med 1998, 21:163-178.
25. Worrel LM, Krahn LE, Sletten CD, et al.: Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. Mayo Clin Proc 2001, 76:384-390.
26. Bennett RM: Mayo Clinic fibromyalgia program. Curr Rheumatol Rep 2002, 4:283-284.
27. Carins D, Mooney V, Crane P: Spinal pain rehabilitation: inpatient and outpatient treatment results and development of predictors for outcome. Spine 1984, 9:91-95.
28. Litschi M, Reiss A, Bühler D, et al.: Interdisciplinary outpatient pain program (IOPP). Swiss Med Wkly 2001, 131 (suppl 126):S24.
29. Adams N, Kennedy T, Chitty G, et al.: A pragmatic controlled trial to assess the effectiveness of a pain management program for fibromyalgia syndrome (FMS) [abstract]. IASP Press 2002, 277-P273.
30. Reilly P. How should we manage fibromyalgia. Ann Rheum Dis 1999, 58:325-326.
31. Shick RD, Burton HJ, Ong-Lam MC, et al.: Treatment outcomes in females with fibromyalgia and females with spinal pain in a multidisciplinary chronic pain program [abstract]. IASP Press 2002, 279-P275.
32. Hurley MV: Muscle, exercise and arthritis. Ann Rheum Dis 2002, 61:673-675.
33. Bosch RE, Saenz MN, Valls EM, et al.: Study of quality of life of patients with fibromyalgia: impact of a health education programme. Aten Primaria 2002, 30:16-21.
34. Bernard AL, Prince A, Edsall P: Quality of life issues for fibromyalgia patients. Arthritis Care Res 2000, 13:42-50.
35. Moldofsky HK: Disordered sleep in fibromyalgia and related myofascial facial pain conditions. Dent Clin North Am 2001, 45:701-713.
36. Jones KD, Burckhardt CS, Clark SR, et al.: A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol 2002, 29:1041-1048. •• Patients with FM can engage in a specially tailored muscle strengthening program and experience an improvement in overall disease activity, without a significant exercise-induced flare in pain.
37. Gordon S, Morrison C: Fibromyalgia and its primary care implications. Med-surg Nursing. 1998, 7:207-216.
38. Robinson T, Burns M: A comparison of clinical outcomes of fibromyalgia patients by age and gender in an interdisciplinary group program [abstract]. IASP Press 2002, 535-P169.
39. Miller LJ, Kubes KL: Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 2002, 36:707-712.
40. Wolfe F, Cathey MA, Kleinheksel SM: Fibrositis (Fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984, 11:814-818.
41. Williams DA, Cary MA, Gronerr KH, et al.: Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002, 29:1280-1286.
42. Busch A, Schachter CL, Peloso PM, et al.: Exercise for treating fibromyalgia syndrome (Cochrane Review). Cochrane Database Syst Rev 2002, (3):CD003786.
43. Martin L, Nutting A, Macintosh BR, et al.: An exercise program in the treatment of fibromyalgia. J Rheumatol 1996, 23:1050-1053.
44. Norregaard J, Lykkegaard JJ, Mehlsen J, et al.: Exercise training in treatment of fibromyalgia. J Musculoske Pain 1997, 5:71-79.
45. Gowans SE, deHueck A, Voss S, et al.: Effect of a randomized, controlled trial on mood and physical function in individuals with fibromyalgia. Arthritis Rheum 2001, 45:519-529. 30-minute exercise classes per week for 23 weeks can improve the mood and physical function of individuals with fibromyalgia.
46. Richards SC, Scott DL: Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ 2002, 325:185. •• Prescribed graded aerobic exercise is a simple, cheap, effective, and potentially widely available treatment for fibromyalgia. The significantly positive effects could be still observed at the 1-year follow up.
47. Evcik D, Kizilay B, Gokcen E: The effects of balneotherapy on fibromyalgia patients. Rheumatol Int 2002, 22:56-59.
48. Buskila D, Abu-Shakra M, Neumann L, et al.: Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int 2001, 20:105-108.
49. Karagulle Z, Donmez A: Balneotherapy for fibromyalgia at the Dead Sea. Rheumatol Int 2002, 21:210-211.
50. Erdl R, Schnizer W: Wirkungen von Kohlendioxid und Schwefelwasserstoff auf die Mikrozirkulation der Haut. Messungen mit dem Laser-Doppler-Flowmeter. Z Phys Med Baln Med Klim 1986, 15:116-120.
51. Gutenbrunner C, Englert G, Neues-Lahusen M, et al.: Analgetische Wirkungen von natürlichen Schwefelbädern und Kältekammerexpositionen bei Fibromyalgie. Phys Rehab Kur Med 1999, 9:56-62.
52. Gamber RG, Shores JH, Russo DP, et al.: Osteopathic manipulative treatment in conjunction with medication relieves pain associated with fibromyalgia syndrome: results of a randomized clinical pilot project. J Am Osteopath Assoc 2002, 102:321-325.
53. Sprott H, Jeschonneck M, Grohmann G, et al.: Microcirculatory changes over the tender points in fibromyalgia patients after acupuncture therapy (measured with laser-Doppler flowmetry). Wien Klin Wochenschr 2000, 112:580-586.
54. Gur A, Karakoc M, Nas K, et al.: Efficacy of low power laser therapy in fibromyalgia: a single-blind, placebo-controlled trial. Lasers Med Sci 2002, 17:57-61.
55. Arnold LM, Hess EV, Hudson JI, et al.: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197. • In a 12-week, flexible-dose, placebo-controlled trial, fluoxetine in dosages more than 20 mg/d (mean dose [± SD], 45 ± 25 mg/d) was found to be significantly effective on pain, fatigue, and depression scores compared with the placebo group and generally well tolerated in women with fibromyalgia.
56. Gur A, Karakoc M, Nas K, et al.: Cytokines and depression in cases with fibromyalgia. J Rheumatol 2002, 29:358-361. • Serum IL-8, IL2r, and Hamilton Depression Rating Scale scores were significantly higher in patients with FM than in the control group (P≤0.01 ). IL-8 was found to be related to pain intensity in patients with FM (r=0.35; P≤0.01). The authors concluded that IL-8 may play an important role in the occurrence of pain in FM.
57. Salemi S, Rethage J, Wollina U, et al.: Detection of IL-1β, IL-6 and TNF-α in skin of fibromyalgia patients. J Rheumatol 2003, 30:146-150. • The detection of IL-1β, IL-6, and TNF-α in FM skin suggests the presence of inflammatory foci (neurogenie inflammation) in the skin of about one-third of FM patients, suggesting an inflammatory component in the induction of pain. This may explain the response to nonsteroidal anti-inflammatory drug therapy in a subset of FM patients.
58. Sprott H, Salemi S, Gay RE, et al.: Elevation of opioid receptor (OR) expression in skin tissues of fibromyalgia (FMS) patients. J Musculoske Pain 2001, 9(suppl 5):77. • The expression of delta opioid receptor [81.0 fold (P=0.001)] and kappa opioid receptor [13.6 fold (P=0.009)] mRNA was significantly increased in FM skin compared with that of healthy controls. No significant differences could be detected in muscle tissues. The data suggest that opioid antinociception can be initiated by activation of opioid receptors present outside of the central nervous system, which could be the result of severe and persistent pain.
59. Panerai AE, Vecchiet J, Panzeri P, et al.: Peripheral Blood Mononuclear Cell β-Endorphin Concentration Is Decreased in Chronic Fatigue Syndrome and Fibromyalgia but Not in Depression: Preliminary Report. Clin J Pain 2002, 18:270-273. • β-endorphin concentrations in peripheral blood mononuclear cells were significantly lower in patients with FM than in normal subjects and depressed patients (P≤0.001 and P≤0.01, respectively). Evaluation of β-endorphin concentrations could represent a diagnostic tool for FM and help with differential diagnosis versus depression.
60. Akkus S, Kutluhan S, Akhan G, et al.: Does fibromyalgia affect the outcomes of local steroid treatment in patients with carpal tunnel syndrome? Rheumatol Int 2002, 22:112-115.
61. Mense S: Neurobiological concepts of fibromyalgia: the possible role of descending spinal tracts. Scand J Rheumatol 2000, 113(suppl):24-29.
62. Crofford LJ: The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. Z Rheumatol 1998, 57(suppl)2:67-71.
63. Neeck G: Pathogenic mechanisms of fibromyalgia. Ageing Res Rev 2002, 1:243-255.
64. Russell IJ, Or MD, Littman, B, et al.: Elevated cerebrospinal fluid levels of substance P in patients with fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
65. Paiva ES, Deodhar A, Jones KD, et al.: Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 2002, 46:1344-1350. •• Three new findings are reported: (1) FM patients have a reduced growth hormone response to exercise, (2) pyridostigmine reverses this impaired response, and (3) defective growth hormone secretion in FM can occur in patients with normal insulin-like growth factor-1 levels. Because pyridostigmine is known to reduce somatostatin tone, it is surmised that the defective growth hormone response to exercise in FM patients probably results from increased levels of scmatostatin, a hypothalamic hormone that inhibits growth hormone secretion.
66. van West D, Maes M: Neuroendocrine and immune aspects of fibromyalgia. BioDrugs 2001, 15:521-531.
67. Bradley LA, Weigent DA, Sotolongo A, et al.: Blood serum levels of nitric oxide (NO) are elevated in women with fibromyalgia (FM): Possible contributions to central and peripheral sensitization. Arthritis Rheum 2000, 43:S173.
68. Jeschonneck M, Grohmann G, Hein G, et al.: Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology (Oxford) 2000, 39:917-921.
69. Morf S, Forster A, Amann B, et al.: Microcirculation changes in patients with fibromyalgia measured by capillary microscopy and laser Doppler fluxmetry: a comparative study with healthy subjects and scleroderma patients. Ann Rheum Dis 2002, 61 (suppl 1):48.
70. Hamaty D, Valentine JL, Howard R, et al.: The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol 1989, 19(suppl):164-168.
71. Buckelew SP: Fibromyalgia: a rehabilitation approach. Am J Phys Med Rehabil 1989, 68:37-42.
72. Littlejohn GO, Walker J: A realistic approach to managing patients with fibromyalgia. Curr Rheumatol Rep 2002, 4:286-292 •• This review article summarizes the present state-of-the-art management approach to fibromyalgia treatment. Biopsychosocial interventions and the growing knowledge of the potential reversibility of fibromyalgia may result in improved outcomes.